Genetic Technologies, 60sec ()

Genetic Technologies (ASX: GTG, NASDAQ Global Market: GENE) is leading-edge genetic testing and reproductive services business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of DNA on health.

Paion, 60sec ()

The company is specializing in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.

Epigenomics, 60sec ()

Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer.

Oxford BioMedica, 60sec ()

Gene therapy and immunotherapy have enormous potential to benefit the lives of patients. Oxford BioMedica is one of the leading companies in this field. We have established a platform of highly innovative technologies to deliver genes that code for therapeutic proteins or induce an immune response.

Wilex, 60sec ()

WILEX’s mission is to develop drugs with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumours.

4SC, 60sec ()

4SC AG (Frankfurt, Prime Standard: VSC/ISIN DE0005753818) discovers and develops small-molecules for autoimmune and cancer indications. 4SC-101, a novel autoimmune modulator, is in a Phase IIb study in rheumatoid arthritis as well as a Phase IIa exploratory study in inflammatory bowel disease. The company’s lead oncology compound, resminostat (4SC-201), a pan-histone-deacetylase inhibitor, is in two Phase II trials in hepatocellular carcinoma and Hodgkin’s Lymphoma. Two further oncology compounds 4SC-203 and 4SC-205 are due to commence Phase I trials. Drug candidates are developed until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.

Magforce, 60sec ()

MagForce Nanotechnologies AG is the global leader in the field of nanotechnology cancer treatment. This revolutionary technology aims to establish a entirely new form of cancer treatment within the near future, using magnetic particles to treat tumors with very minimal side effects, thus enhancing patient quality of life. The technology and its related equipment are currently in the final phases of clinical trials. Until these have been successfully concluded, the products can only be used in conjunction with clinical trials. The products can only be sold and used in normal clinical practice once they have received regulatory approval from the responsible authorities.

MediGene, 60sec ()

MediGene's vision is the expansion of the potentials in medicine by means of utilizing biotechnology in a responsible manner. We apply state-of-the-art technologies in the development of innovative drugs for the treatment of cancer and autoimmune diseases. MediGene pursues the strategy of integrating all core areas of a modern biopharmaceuticals company from research to drug development and commercialization.

Agennix, 60sec ()

Agennix AG is a publicly traded biopharmaceutical company focused on developing novel anti-cancer therapies. The Company was formed by the combination of GPC Biotech AG and Agennix Incorporated. The Company’s most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for wound healing. Agennix is a transatlantic company with sites in Munich, Germany; Princeton, New Jersey and Houston, Texas.

Algeta, 60sec ()

Algeta is an oncology company developing treatments for bone metastases and disseminated tumor types. The company's lead product Alpharadin is targeting bone metastases which occur frequently in major cancers including hormone-refractory prostate cancer, breast, lung, kidney and thyroid. The treatment of bone metastases represents an area of high unmet medical need.

Response Biomedical, 60sec ()

Response Biomedical develops, manufactures and markets rapid point-of-care (POC) diagnostic tests for use with our proprietary RAMP® (Rapid Analyte Measurement Platform) System for clinical and environmental applications. RAMP® has set a new performance standard in rapid diagnostic testing by providing lab quality information in minutes.

YM BioSciences, 60sec ()

RedPoint Bio, 60sec ()

Redpoint is utilizing its knowledge of the biology of taste and its relationship to metabolic processes, satiety and diabetes to focus its research programs on the development of healthier foods and new therapeutic approaches to the treatment of diabetes and obesity.

How Would You Define Cell Therapy? (02:28)

We've asked guests and panelists of the 2009 Phacilitate Cell & Gene Therapy forum to answer the following question:

How Would You Define Cell Therapy?

Here are their answers, mashed up by yours truly.

Are We Going to See New Cell Therapy Products in the Next 2-3 Years? (01:31)

We've asked guests and panelists of the 2009 Phacilitate Cell & Gene Therapy forum to answer the following question:

Are We Going to See New Cell Therapy Products in the Next 2-3 Years?

Here are their answers, mashed up by yours truly.

How Many Cell Therapy Products Are On the Market Today? (01:27)

We've asked guests and panelists of the 2009 Phacilitate Cell & Gene Therapy forum to answer the following question:

How Many Cell Therapy Products Are On the Market Today?

here are their answers, mashed up by yours truly.

What Are Some of the Exciting Things Happening in Cell Therapy? (02:06)

We've asked guests and panelists of the 2009 Phacilitate Cell & Gene Therapy forum to answer the following question:

What Are Some of the Exciting Things Happening in Cell Therapy?

Here are their answers, mashed up by yours truly.

Maxcyte, 60sec Pitch (01:08)

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary, non-viral, ex vivo cell loading technology provides safety, scalability and reproducibility capabilities which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers.

Florida Biologix, 60sec Pitch (01:19)

Florida Biologix® is a biopharmaceutical contract services provider that specializes in developing, manufacturing, purifying, testing and filling Phase I and II cGMP biologic clinical trial material on time and at a reasonable price.

Athersys Inc., 60sec Pitch (01:09)

Athersys is a developing a pipeline of therapeutic products with “best-in-class” potential. The most advanced product in development is MultiStem, a patented and proprietary stem cell therapy that in the past year has reached clinical stage in 3 areas, including treating cardiovascular disease (acute myocardial infarction), cancer treatment support (leukemia and lymphoma), and ischemic stroke. The company believes MultiStem represents a potential breakthrough in stem cell medicine, since it is the first off-the-shelf stem cell product with each of the following characteristics:

(1) it can be manufactured on an industrial scale far greater than any other stem cell product, and conveniently stored in frozen form;

(2) it can be administered without tissue matching or any immune suppressive drugs, making it analogous to type O blood;

(3) it has the potential to deliver a therapeutic benefit in multiple ways, primarily through the regulated production of multiple factors that control inflammation and immune response, promote tissue repair and healing, protect damaged or injured cells, and deliver other benefits.

MultiStem exhibits a consistent safety profile, and has demonstrated therapeutic effectiveness across a range of disease indications. MultiStem was recently awarded the 2008 Product Innovation of the Year by Frost & Sullivan, who designated it as best-in-class among stem cell and regenerative medicine technologies. In addition to MultiStem, Athersys is developing a portfolio of pharmaceutical candidates for neurologic disease and certain metabolic indications such as obesity.

ZelosTherapeutics, Inc. 60sec Pitch ()

Zelos Therapeutics is developing therapeutics for the treatment of osteoporosis and other bone diseases. Our lead compound, ZT-031, is entering Phase 3 registration studies and has the potential to become a leading therapy to treat osteoporosis in the growing PTH market.

Xoma, Ltd. 60sec Pitch ()

XOMA discovers, develops and manufactures therapeutic antibody agents designed to treat inflammatory, autoimmune, infectious and cancerous diseases and is engaged in more than 16 active development projects. The Company's expanding pipeline includes XOMA 052, an anti-IL-1beta antibody, and XOMA 629, a synthetic antimicrobial peptide compound derived from bactericidal/permeability-increasing protein.

Vivus Inc. 60sec Pitch ()

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity, diabetes and sexual health.

Vical Incorporated, 60sec Pitch ()

We research and develop biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Osiris Therapeutics, Inc. 60sec Pitch ()

Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory graft versus host disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product.

Newron Pharmaceuticals, SPA, 60sec Pitch ()

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on novel therapies for diseases of the Nervous System and pain.

MiMedx Group Inc. 60sec Pitch ()

MiMedx Group, Inc., (MDXG) is an integrated developer, manufacturer, and marketer of patent protected, spine and orthopedic implants which represent breakthroughs in the treatment of trauma and disease.

Mannkind Corporation, 60sec Pitch ()

Mannking Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Dyax Corp. 60sec Pitch ()

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.

Cynvec, LLC, 60sec Pitch ()

Cynvec is a development stage, NYC based company formed in June 2004 to develop Sindbis-based viral vectors as oncolytic therapeutics, through IP licensed exclusively from NYU.

Cell Therapeutics, Inc. 60sec Pitch ()

Cell Therapeutics Inc. (CTI) develops, acquires and commercializes novel treatments for cancer. Its goal is to build a leading, vertically-integrated biopharmaceutical company with a diversified portfolio of proprietary cancer drugs. Its research and in-licensing activities are focused on identifying new, less toxic and more effective ways to treat cancer.

Acucela Inc. 60sec Pitch ()

Acucela Inc. is a clinical-stage biotechnology company focused on developing new drug therapies for blinding eye diseases such as age-related macular degeneration (AMD), Stargardt disease, diabetic retinopathy and retinopathy of prematurity, as well as dry eye.

Synta Pharmaceuticals Corp. 60sec Pitch ()

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.

Novelos Therapeutics, Inc. 60sec Pitch ()

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis.

MorphoSys AG, 60sec Pitch ()

MorphoSys is one of the world's leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing the next generation of antibodies not only for research and diagnostics purposes, but also as highly effective and precise therapeutics. HuCAL® (Human Combinatorial Antibody Library) is a very powerful technology for the rapid and automated production of specific antibodies.

The Female Health Company, 60sec Pitch ()

The Female Health Company (FHC) owns certain world-wide rights to the Female Condom (FC1 and FC2) – a revolutionary option offering women dual protection against both sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.

EyeGate Pharma, 60sec Pitch ()

EyeGate Pharma is a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics to the front and back tissues of the eye. The company’s lead program is EGP-437 being developed for severe uveitis, dry eye and corneal graft rejection.

Depomed, Inc. 60sec Pitch ()

Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuFormTM drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract.

Delcath Systems, Inc. 60sec Pitch ()

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy.

BioSpecifics Technologies Corp. 60sec Pitch ()

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications: Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis).

Antigenics Inc. 60sec Pitch ()

Antigenics is a biotechnology company working to develop treatments for cancers and infectious diseases.

Alchemia Limited, 60sec Pitch ()

Alchemia is an Australian biopharmaceutical company employing innovative technologies for the synthesis of complex carbohydrates, the targeting of cancer drugs to tumors and the discovery of medicinal drugs for human use.

Agile Therapeutics, Inc. 60sec Pitch ()

Agile Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative women’s healthcare products that address unmet needs.

Suven Life Sciences, 60sec Pitch ()

Suven Life Sciences Limited is Hyderabad based life sciences company a pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995. Suven in its endeavor to become collaborative research partner (CRP) for global life science companies has embarked on new business model “Drug Discovery and Development Support Services” (DDDSS) with the onset of Intellectual Property Regime in India since January 2005.

Stem Cell Therapeutics Corp. 60sec Pitch ()

Stem Cell Therapeutics Corp. is a Canadian biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.

Oncolytics Biotech, Inc. 60sec Pitch ()

Founded in 1998, Oncolytics Biotech Inc. is a public, Canadian-based biotechnology company that is developing a novel,virus-based cancer therapeutic. The reovirus has been shown to selectively kill certain cancer cells without damaging healthy cells and tissues.

Numoda Corporation, 60sec Pitch ()

As a growth partner to life science companies, Numoda Corporation opens up clients’ options fast, through Improved Norms™, including data lock within hours of the last patient visit. Information services and process management are applied for improved norms in corporate and business development, financial, and product development.

Neotropix, Inc. 60sec Pitch ()

Neotropix began operations in 2005 to develop and commercialize naturally derived, systemically deliverable oncolytic viruses for the treatment of solid tumors.

Interleukin Genetics, Inc. 60sec Pitch ()

Interleukin Genetics is a leading, genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market.

Infinity Pharmaceuticals, Inc. 60sec Pitch ()

The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

Converted Organics, Inc. 60sec Pitch ()

Converted Organics Inc. is transitioning from a development stage company (first reported revenues were in February 2008) to a fully operational company that seeks to construct processing facilities that will use food waste as raw material to manufacture all-natural soil amendment products combining nutritional and disease suppression characteristics.

Cleveland Biolabs, Inc. 60sec Pitch ()

Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to acute stresses.

Biovest International, 60sec Pitch ()

Biovest International develops personalized immunotherapies for life threatening cancers of the blood system.

Arana Therapeutics, Inc. 60sec Pitch ()

Arana Therapeutics Limited, created through the merger of Peptech Limited and EvoGenix Limited in August 2007, is a biotechnology company dedicated to developing and providing antibody and peptide-based human therapeutic products for the treatment of cancer and inflammatory diseases.

Antisoma PLC, 60sec Pitch ()

Antisoma is an oncology-focused biotech company with operations in the UK and the US. Antisoma’s strategy is to acquire promising early-stage drug candidates, develop these through clinical trials, and bring them to market itself or through partnerships.

Akela Pharma Inc. 60sec Pitch ()

AKELA Pharma Inc. (TSX: AKL) is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation market.

New York Success in Biotech, More than Meets the Eye? (07:52)

Is NY a more expensive place to start a Biotech company vs. MA or CA? Nathan Tinker (Executive Director, NYBA) argues it isn't and that NY really presents a great number of opportunities for Biotech Companies. He supports this with example of NY Successes, including ImClone, OSI Pharmaceuticals, and Regeneron. Nathan also discusses VC activity in NY, the NY City vs. NY State dichotomy, and the proximity with NJ Pharma, Nathan also touches on the $.5BN bioscience infrastructure driving RND, as well as the state of phase 2-3 pipelines.

Building Biotech in New York, NYS Economic Development Council (04:57)

Debra Flack tells us about the New York State Economic Development Council and its activities. Debra underlines the strength of New York with respect to Science, Academia, and Finance. She mentions the commitment and grant programs that have been put in place by the state, as well as the lobbying efforts to reduce the tax burden, and the cost of doing business, both in the City and the State.

Austria: Connecting Europe by Way of Vienna ()

Gisbert Myer explains why Austria is a strategic business location in Europe, as connects its East and West, presents generous cash incentives for R&D, and has attractive corporate tax rates.

Austria: From Academia to Business ()

Michaela Fritz explains how Austria's strength in academic research - particularly infectious diseases and oncology, has created a new dynamism on the business side. She highlights some of the recent business successes and government programs that are giving Austria a critical mass in European Biotech & Pharma.

China's Biotech, Rapidly Emerging? ()

James Zhu sees formidable potential for Chinese Biotech and projects its exponential growth as improving IP environment, very sizeable government funding of R&D, and fast growing GDP create numerous opportunities to collaborate with China.

Dubai: Developing a New Center of Excellence ()

How is Dubai developing its Biotechnology Industry? Dr. Al Khayat  tells us about the emirate's ambition to create a center of excellence for the region, the business and science infrastructure it is leveraging, and the incentives that have been put in place to foster the growth of this young industry.

India: Paradigm Shift, IP, Drug Discovery, and Innovation ()

Nandita Chandavarkar comments on the paradigm shift in intellectual property. India better understands the value of IP as it creates its own. A very clear legislature has been put in place by the government to protect the interests of Bio and Pharma companies.

Ireland: Commitment to BioPharma and Medical Devices. ()

Marian Byron tells us of the importance of the BioPharma and MedDevices industry to the economy of Ireland. Ireland is totally focused toward BioPharma & MedDevices. Having consolidated a manufacturing base, Ireland is now moving to establish a strong R&D base and putting in place multiple tax incentives and state aids to promote the development of this industry.

Ireland: Manufacturing, Start Ups, Universities, Research. ()

Dr. Cormack Kilty tells us about his Dublin-based company, Biotrin International, developer novel biomarkers of organ damage. He sees the significant investments in universities and research, as well as the support for start ups and presence of large Pharma groups as the drivers of industry growth.

Ireland: Success, and Investment for R&D and Innovation. ()

Barry O'Leary highlights the $6bn investment in Ireland that the world's leading companies have made, its huge emphasis on R&D and innovation, and the great talent it contributes to the industry.

Israel Biotech: Flourishing Research,Innovative Companies. ()

You'll see here Israel Life Science Industry Board Members Zeev Zelig and Yossi Bornstein personify the spirit of the Israel biotechnology industry. Many high tech companies have established R&D facilities in Israel. The research evolves so rapidly that Israel is constantly looking to build collaborations that can help bring these new technologies to market.

Japan: Services for Foreign Biotech Companies ()

Sato San explains investment promotion is very important to the Japanese government, and that's why it is offering free executive recruiting, marketing services, and office space for foreign companies that are developing their activities on the archipelago. 

Spain: Fast Pace Growth ()

A study a various statistics reveals a higher than 25% growth per year in the Spanish biotechnology industry. External investment is just starting as companies are gaining a critical mass that is now piquing the interest of Venture Capitalists.Spain's growth in BioFuel, AgroFood, and Human Health remains well equilibrated.

Switzerland: Hidden Champions ()

Great financial markets and increasing VC investments and exits make Switzerland the 9th largest Biotech enterprise in the world. It has a long standing history in pharmaceuticals research and commercialization. In the next 5 years, the SWISS Biotech Association will be focusing on advocacy, building infrastructural offers for expensive Biotech on a national level, and starting to promote itself.

California: The State's Ambition is to Remain Number One ()

The birthplace of biotechnology is betting on its workforce, research centers, and wonderful environment to attract and retain biotechnology companies. California appreciates the value of biotechnology and wishes to remain the leader in research manufacturing in the United States.

Florida: Scripps, Building a World Class Research Institute ()

Harry Orf explains the reasoning behind the development of Scripps, and what made Florida a particularly attractive location. He also comments on the peer-to-peer collaborations this biomedical research facility is meant to foster.

Florida: After Scripps, Torrey Pines sets Research Unit ()

Torrey Pines intends to bring the world class science and entrepreneurial spirit to Florida. Dr Houghten tell us how Torrey Pines fell in love with Port Saint Lucie, and how Torrey Pines combines collaboration and a focus on practical scientific applications to grow rapidly and successfully.

Maryland: Biotechnology is a Top Priority ()

Maryland is incredibly excited about Biotechnology, and its prospects for improving the human condition and the state's economy. That is why they are investing in research, public private partnerships, and the incubators that are creating the technologies of tomorrow.

Massachussets: Supercluster, Tremendous Innovation ()

Allan Blair tell us why the state of Massachusetts is known as the "heart and soul" of Biotech. He also presents some of the future challenges for the state, as well incentives for companies to relocate to Massuchusetts (including state-wide, individual region, and site specific)

North Carolina: Skilled Workforce. ()

NC believes the quality of the workforce is the one greatest determinent of success for biotech and pharma companies. That is why the state is focusing it efforts on workforce training which encompassesfree training for any company moving to region, links to colleges and K-12, and their new science programs.

Pennsylvania: Innovation, Finance, Infrastructure ()

PA's innovative governor is putting together all kinds of incentive packages to help companies. These include financing through state funds and the strong VC network, as well as a variety of support services such as legal, accounting, partnerships, and site selection.

Maryland: Driving Economic Development through Biotech Investme ()

Dr Mahan discusses the academic and federal research assets that make Maryland a favorite place for Biotech companies. Dr. Mahan also presents Maryland's new tax incentives for corporate and individual Biotech investors.

Transport's CEO on Drug-Device Convergence ()

Dr Dennis I.Goldberg, on Drug-Device  convergence and its application to treatment of dermatological diseases.

Dyadic's CEO on Bio-Energy ()

Mark Emelfarb, tell us about Dyadic International's cellulose-basd technology and its applications, including Bio-Energy.

Affymax: the Technology, Timeline, and Success/Risk Factors ()

We asked Arlene Morris what kind of advantage the use of peptide based hematide product presented, what her development timeline looked like, and what critical success and risk factors she perceived as most important.

Boston Life Sciences's Altropane and Cethrin ()

Ken Rice tells us about Altropane, a molecular imaging agent that can change the treatment of Parkinsons Disease, and Cethrin an enzyme inhibitor for axon regeneration in spinal injurues. He discusses the impact on patient health, the time to market, and the critical success and risk factors.